ORPHA:93126
Pauci-immune glomerulonephritis
Publications
1,104
Trials
0
Interventional, condition-specific
Researchers
1,084
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare small vessel vasculitis associated with rapidly glomerulonephritis (GN) and clinically characterized by renal manifestations such as urinary abnormalities (hematuria and/or proteinuria) and hypertension leading to renal failure within days or weeks, and distinguished by the absence of immune deposits on immunofluorescent microscopy. The disease can occur as a renal-limited disease or as a component of systemic necrotizing small-vessel vasculitis.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0019641
- UMLS:C0343196
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
1,104 matched papers (824 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 117 for broader category glomerulonephritis
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
1,104
1,104 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
1,104 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
824 in the last 10 years · low confidence
Phrase hits: 1,104 · MeSH hits: 0
Who's working on it?
1,084
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Lee SW5 papers · 2025
Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Papers in Europe PMC - 02Lionaki S5 papers · 2025
Department of Nephrology and Transplantation Unit, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Papers in Europe PMC - 03Park YB5 papers · 2025
Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Papers in Europe PMC - 04Geetha D4 papers · 2026
Division of Nephrology, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
Papers in Europe PMC - 05Ha JW4 papers · 2025
Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Papers in Europe PMC - 06Kronbichler A4 papers · 2026
Department of Internal Medicine IV, Nephrology and Hypertension, Medical University Innsbruck, Innsbruck, Austria.
Papers in Europe PMC - 07Liapis G4 papers · 2025
1 Department of Pathology, Medical School, National and Kapodistrian University of Athens, Laiko Hospital, Athens, Greece.
Papers in Europe PMC - 08Kalogeropoulos P3 papers · 2025
Department of Nephrology and Transplantation Unit, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Papers in Europe PMC - 09Marinaki S3 papers · 2024
Department of Nephrology and Transplantation Unit, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Papers in Europe PMC - 10Song JJ3 papers · 2025
Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 117 trials are registered for glomerulonephritis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
low confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
117 interventional trials matched glomerulonephritis, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: glomerulonephritis
117
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT05654506·RECRUITING·Daratumumab for Treatment of Proliferative Glomerulonephritis With Monoclonal Immune Deposits
Conditions: Proliferative Glomerulonephritis With Monoclonal IgG Deposits·Matched via name phrase
- NCT07038382·RECRUITING·A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis
Conditions: Membranous Nephropathy · Lupus Nephritis (LN)·Matched via name phrase
- NCT06623877·NOT YET RECRUITING·Using Renal Elastography Measurements for Evaluation of Glomerulonephritis Patients
Conditions: Evaluation of Biopcy Proven Glomerulonephritis Patients by Renal Shear Wave Elastography·Matched via name phrase
- NCT06047171·RECRUITING·Rescue of Nephrons With ALE.F02 (RENAL-F02)
Conditions: Glomerulonephritis Rapidly Progressive·Matched via name phrase
- NCT07431931·NOT YET RECRUITING·Optimizing Referral Pathways for Patients With Hematuria and Moderate-Severe Proteinuria
Conditions: Referral and Consultation · Glomerulonephritis · Hematuria · Proteinuria·Matched via name phrase
- NCT06295770·RECRUITING·Obinutuzumab in Treatment of Fibrillary Glomerulonephritis
Conditions: Fibrillary Glomerulonephritis·Matched via name phrase
- NCT06209736·RECRUITING·Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN
Conditions: C3 Glomerulopathy · Idiopathic Immune Complex-Mediated Glomerulonephritis·Matched via name phrase
- NCT06889948·RECRUITING·The Effect of Daratumumab in Patients with Monoclonal Gammopathy of Renal Significance (MGRS) in Finland
Conditions: Kidney Failure · Paraproteinemias · Glomerulonephritis·Matched via name phrase
- NCT00977977·RECRUITING·Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
Conditions: Nephrotic Syndrome · Proteinuria · Autoimmune Disease · Glomerular Disease·Matched via name phrase
- NCT06528015·NOT YET RECRUITING·Efficacy and Safety of Probiotics Combined With Enteric-coated Budesonide Capsules in Patients With Primary IgA Nephropathy
Conditions: Glomerulonephritis, IGA · Probiotics · Budesonide·Matched via name phrase
- NCT05517980·NOT YET RECRUITING·Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat Glomerulonephritis
Conditions: Glomerulonephritis·Matched via name phrase
- NCT06676384·RECRUITING·Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?
Conditions: IgA Nephropathy · Renal Insufficiency, Chronic · IgA Vasculitis · IGA Glomerulonephritis·Matched via name phrase
- NCT06858319·RECRUITING·Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
Conditions: Kidney Diseases · Kidney Diseases, Chronic · Urological Diseases · Glomerulonephritis·Matched via name phrase
- NCT05996731·RECRUITING·Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases
Conditions: Atypical Hemolytic Uremic Syndrome · Membranoproliferative Glomerulonephritis · Autosomal Dominant Polycystic Kidney · Healthy·Matched via name phrase
- NCT07096986·NOT YET RECRUITING·Impact of Dapagliflozin for the Regulation of Immunological Activity in Membranous Nephropathy
Conditions: Glomerulonephritis·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Pauci-immune glomerulonephritis"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Pauci-immune glomerulonephritis"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"glomerulonephritis"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (1104) is extremely high with unknown/missing prevalence — treat as possible over-matching, not proven research intensity
Ingested 2026-07-27T04:07:26.205Z
